Table 2.
Characteristics of patients included in the secondary analysis of three randomized controlled trials
| Female sex | 1378 (47.1) |
| Age | 60.0 (49.0–70.0) |
| Body mass index | 26.7 (22.5–32.6) |
| Race | |
| White | 1794 (61.3) |
| Black or African American | 515 (17.6) |
| Hispanic or Latino | 395 (13.5) |
| Other | 102 (3.5) |
| Comorbidities | |
| Diabetes mellitus | 921 (31.5) |
| Chronic lung disease | 494 (16.9) |
| Chronic kidney disease | 355 (12.1) |
| Liver disease | 304 (10.4) |
| Hematologic malignancy | 189 (6.5) |
| Solid tumor | 458 (15.6) |
| Prior myocardial infarction | 217 (7.4) |
| Congestive heart failure | 387 (13.2) |
| Primary risk factor for ARDS | |
| Pneumonia | 918 (31.4) |
| Extrapulmonary sepsis | 1694 (57.9) |
| Organ failure at baseline | |
| Cardiovascular | 1413 (48.3) |
| Renal | 832 (28.4) |
| Hepatic | 344 (11.8) |
| Non-coagulation SOFA score | 3.0 (1.0–5.0) |
| White blood cell count (/µL) | 11,755 (6,952–17,620) |
| Hematocrit (%) | 34.6 (29.2–39.2) |
| Interleukin-6 (pg/mL) | 48.8 (17.1–201.5) |
| Baseline platelets (/µL) | 203,000 (137,000–284,000) |
| Development of ARDS | 104 (3.6) |
Data are presented as median (interquartile range) or numbers (percentages)
Data from 2927 subjects at risk for ARDS were considered for the secondary analysis
Data on white blood cell count were available only for VIOLET [18] and CLOVERS [19] trials
Data on hematocrit were available only for CLOVERS [19] trial
Data on plasma interleukin-6 levels were available only for VIOLET [18] and ASTER [20] trials
Abbreviations: ARDS acute respiratory distress syndrome, SOFA Sequential Organ Failure Assessment